John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

MENU

The combined use of hypofractionated stereotactic radiotherapy and new anticancer drugs Volume 4, issue 3, Mai-June 2018

Authors
1 MD, PhD Institut de cancérologie Jean Godinot
Département d’oncologie radiothérapie
1, rue du Général Koenig
51726 Reims cedex
France
2 MD, PhD Centre François Baclesse Archade
Département d’oncologie radiothérapie
3, avenue Général Harris
14000 Caen
France
* Tirés à part
  • Key words: stereotactic radiotherapy, targeted therapies, immunotherapy
  • DOI : 10.1684/ito.2018.0118
  • Page(s) : 146-51
  • Published in: 2018

As a result of recent advances in oncologic systemic and local ablative therapy, treatments have become more and more effective in terms of local control and overall survival. Thus, targeted therapy, immunotherapy, and hypofractionated stereotactic radiotherapy have changed how patients are managed, especially in cases of oligometastatic disease, and play an important role in personalized treatment of metastatic disease. Clinical data, however, are still limited. This review aims to outline current knowledge on the combination of hypofractionated stereotactic radiotherapy and targeted therapy/immunotherapy.